{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T04:48:46Z","timestamp":1747284526161},"reference-count":26,"publisher":"Japanese Society of Internal Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,2,15]]},"DOI":"10.2169\/internalmedicine.5615-20","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T22:12:59Z","timestamp":1601417579000},"page":"557-561","source":"Crossref","is-referenced-by-count":2,"title":["Late-onset Hereditary ATTR Amyloidosis with a Novel p.P63S (P43S) <i>Transthyretin<\/i> Variant"],"prefix":"10.2169","volume":"60","author":[{"given":"Yuya","family":"Aono","sequence":"first","affiliation":[{"name":"Department of Cardiology, National Hospital Organization Kyoto Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Hamatani","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National Hospital Organization Kyoto Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagaaki","family":"Katoh","sequence":"additional","affiliation":[{"name":"Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayuko","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Clinical Laboratory Science Division, Shinshu University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuya","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Japan"},{"name":"Center for Medical Genetics, Shinshu University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahide","family":"Yazaki","sequence":"additional","affiliation":[{"name":"Clinical Laboratory Science Division, Shinshu University Graduate School of Medicine, Japan"},{"name":"Institute for Biomedical Sciences, Shinshu University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuyuki","family":"Kametani","sequence":"additional","affiliation":[{"name":"Department of Dementia and Higher Brain Function, Tokyo Metropolitan Institute of Medical Science, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moritake","family":"Iguchi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National Hospital Organization Kyoto Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuko","family":"Murakami","sequence":"additional","affiliation":[{"name":"Clinical Laboratory, National Hospital Organization Kyoto Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National Hospital Organization Kyoto Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National Hospital Organization Kyoto Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Akao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National Hospital Organization Kyoto Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Sekijima","sequence":"additional","affiliation":[{"name":"Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Japan"},{"name":"Institute for Biomedical Sciences, Shinshu University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry 86: 1036-1043, 2015."},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid 25: 215-219, 2018.","DOI":"10.1080\/13506129.2018.1549825"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Cornwell GG III, Murdoch WL, Kyle RA, Westermark P, Pitkanen P. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med 75: 618-623, 1983.","DOI":"10.1016\/0002-9343(83)90443-6"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Westermark P, Sletten K, Johansson B, Cornwell GG III. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A 87: 2843-2845, 1990.","DOI":"10.1073\/pnas.87.7.2843"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Plante-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol 10: 1086-1097, 2011.","DOI":"10.1016\/S1474-4422(11)70246-0"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 8: 31, 2013.","DOI":"10.1186\/1750-1172-8-31"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Holmgren G, Ericzon BG, Groth CG, et al. Clinical improvement and amyloid regression after liver-transplantation in hereditary transthyretin amyloidosis. Lancet 341: 1113-1116, 1993.","DOI":"10.1016\/0140-6736(93)93127-M"},{"key":"8","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","volume":"310","author":"JL Berk","year":"2013","unstructured":"8. Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 310: 2658-2667, 2013.","journal-title":"JAMA The Journal of the American Medical Association","ISSN":"http:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79: 785-792, 2012.","DOI":"10.1212\/WNL.0b013e3182661eb1"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379: 1007-1016, 2018.","DOI":"10.1056\/NEJMoa1805689"},{"key":"11","unstructured":"11. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379: 11-21, 2018."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for aatients with hereditary transthyretin amyloidosis. N Engl J Med 379: 22-31, 2018.","DOI":"10.1056\/NEJMoa1716793"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Tsuchiya-Suzuki A, Yazaki M, Sekijima Y, Kametani F, Ikeda SI. Steady turnover of amyloid fibril proteins in gastric mucosa after liver transplantation in familial amyloid polyneuropathy. Amyloid 20: 236-243, 2013.","DOI":"10.3109\/13506129.2013.807790"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Sekijima Y, Yazaki M, Oguchi K, et al. Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis. Neurology 87: 773-781, 2016.","DOI":"10.1212\/WNL.0000000000003001"},{"key":"15","unstructured":"15. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-Art review. J Am Coll Cardiol 73: 2872-2891, 2019."},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation 135: 1357-1377, 2017.","DOI":"10.1161\/CIRCULATIONAHA.116.024438"},{"key":"#cr-split#-17.1","unstructured":"17. Sekijima Y. Hereditary Transthyretin Amyloidosis. In: GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. University of Washington, Seattle, 1993-2020 [Internet]. [updated 2018 Dec 20"},{"key":"#cr-split#-17.2","unstructured":"cited 2020 Jun 10]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1194\/"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ueda M, Sekijima Y, Koike H, et al. Monitoring of asymptomatic family members at risk of hereditary transthyretin amyloidosis for early intervention with disease-modifying therapies. J Neurol Sci 414: 116813, 2020.","DOI":"10.1016\/j.jns.2020.116813"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Schmidt HH, Barroso F, Gonz\u00e1lez-Duarte A, et al. Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy. Muscle Nerve 54: 353-360, 2016.","DOI":"10.1002\/mus.25210"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 336: 466-473, 1997.","DOI":"10.1056\/NEJM199702133360703"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Yamashita T, Hamidi Asl K, Yazaki M, Benson MD. A prospective evaluation of the transthyretin Ile122 allele frequency in an African-American population. Amyloid 12: 127-130, 2005.","DOI":"10.1080\/13506120500107162"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Jiang X, Buxbaum JN, Kelly JW. The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis. Proc Natl Acad Sci U S A 98: 14943-14948, 2001.","DOI":"10.1073\/pnas.261419998"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Sekijima Y, Wiseman RL, Matteson J, et al. The biological and chemical basis for tissue-selective amyloid disease. Cell 121: 73-85, 2005.","DOI":"10.1016\/j.cell.2005.01.018"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Quarta CC, Buxbaum JN, Shah AM, et al. The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med 372: 21-29, 2015.","DOI":"10.1056\/NEJMoa1404852"},{"key":"25","unstructured":"25. Buxbaum JN, Ruberg FL. Transthyretin V122I (pV142I) * cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans. Genet Med 19: 733-742, 2017."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/4\/60_5615-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T05:52:13Z","timestamp":1669009933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/4\/60_5615-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5615-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]}}}